Sandoz

At Sandoz, our purpose is to pioneer access for patients. Our purpose shines through in our rich heritage, as in our plans for the future. Our vision is to be the world's leading and most valued generics and biosimilar company: valued for how we run our business, but also for the positive impact we have on society. That's how we will deliver sustainably on our purpose.

Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines. 

Sandoz is committed to increasing patient access to high-quality biosimilars in the UK. We annually supply approximately 123 million packs of medicines to UK NHS patients.1 Our broad portfolio is spearheaded by our global leadership position in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the foundation of global healthcare. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.

1. Sandoz. Data on file. MLR: 280481 | April 2023

413950 | February 2024